Influence of mibefradil on Ca2+ influx induced by vasoactive hormones or depletion of intracellular calcium stores

Arzneimittel-Forschung/Drug Research

Volumn 47, Issue 3, 1997, Pages 244-247

  Cheglakov, Ivan B ^a   Bochkov, Valery N ^a   Tkachuk, Vsevolod A ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

calcium antagonists; calcium channels; CAS 116666 63 8; mibefradil; Ro 405967, effects on Ca2+ influx

Indexed keywords

ANGIOTENSIN; CALCIUM ANTAGONIST; MIBEFRADIL; 2,5 DI TERT BUTYLHYDROQUINONE; 2,5-DI-TERT-BUTYLHYDROQUINONE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN II; BENZIMIDAZOLE DERIVATIVE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; ENZYME INHIBITOR; FLUORESCENT DYE; FURA 2; HYDROQUINONE DERIVATIVE; TETRALIN DERIVATIVE; THAPSIGARGIN; VASOCONSTRICTOR AGENT;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; NONHUMAN; RABBIT; SMOOTH MUSCLE; ANIMAL; CELL MEMBRANE; CELL MEMBRANE POTENTIAL; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; PHYSIOLOGY; THROMBOCYTE; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; BENZIMIDAZOLES; BLOOD PLATELETS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM-TRANSPORTING ATPASES; CELL MEMBRANE; ENZYME INHIBITORS; FLUORESCENT DYES; FURA-2; HYDROQUINONES; MEMBRANE POTENTIALS; MIBEFRADIL; MUSCLE, SMOOTH, VASCULAR; RABBITS; TETRAHYDRONAPHTHALENES; THAPSIGARGIN; VASOCONSTRICTOR AGENTS;

EID: 0031092335     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Clozel, J. P., Osterrieder, W., Kleinbloesem, C. H. et al, Cardiovasc. Drug Rev. 9, 4 (1991)
2. Hefti, G., Clozel, J. P., Osterrieder, W., Arzneim.-Forsch./Drug Res. 40, (I), 417 (1990)
3. Schmitt, R., Kleinbloesem, C. M., Schroeter, N. et al., Clin. Pharmacol. Ther. 52, 314 (1992)
4. Orito, K., Satoh, K., Taira, N., J. Cardiovasc. Pharmacol. 22, 293 (1993)
5. Clozel, J. P., Banken, L., Osterrieder, W., J. Cardiovasc. Pharmacol. 14, 713 (1989)
6. Osterrieder, W., Holck, M., J. Cardiovasc. Pharmacol. 13, 754 (1989)
7. Clozel, J. P., Veniant, M., Osterrieder, W., J. Cardiovasc. Drugs Ther. 4, 731 (1990)
8. Godfraind, T., Morel, N., Wibo, M., Trends Pharmacol. Sci. 9, 37 (1988)
9. Fang, L. M., Osterrieder, W., Eur. J. Pharmacol. 196, 205 (1991)
10. Porzig, H., Rev. Physiol. Pharmacol. 114, 210 (1990)
11. Mishra, S. K., Hermsmeyer, K., J. Pharmacol. Exp. Ther. 269, 178 (1994)
12. Mishra, S. K., Hermsmeyer, K., Circ. Res. 75, 144 (1994)
13. Cheglakov, I. B., Hahn, M., Tkachuk, V. A. et al., Cardiovasc. Drugs Ther. 9, 815 (1995)
14. Taylor, C. W., Trends Pharmacol. Sci. 11, 269 (1990)
15. Shirinsky, V. P., Birukov, K. G., Sobolevsky, A. V. et al., Am. J. Hypertension 5, 124S (1992)
16. Tsien, R. Y., Pozzan, T., Rink, T. J., J. Cell. Biol. 94, 353 (1982)
17. Grinkiewicz, G., Poenie, M., Tsien, R. Y., J. Biol. Chem. 260, 3440 (1985)
18. Tsien, R. Y., Biochem. 19, 2396 (1980)
19. Avdonin, P. V., Cheglakov, I. B., Tkachuk, V. A., Eur. J. Biochem. 198, 267 (1991)
20. Nelson, E. J., Li, C. C., Bangalore, R. et al., Biochem. J. 302, 147 (1994)
21. Bian, K., Hermsmeyer, K., Naunyn-Schmiedeberg's Arch. Pharmacol. 348, 191 (1993)
22. Spedding, M., Paoletti R., Pharmacol. Rev. 44, 363 (1992)
23. Dolphin, A. C., Annu. Rev. Physiol. 52, 243 (1990)
24. Hughes, A. D., Schachter, M., Cell Calcium 15, 317 (1994)
25. Burnay, M. M., Python, C. P., Vallotton, M. B. et al., Endocrinology 135, 751 (1994)
26. Bode, H. P., Goke, B., FEBS Lett. 339, 307 (1994)
27. Premack, B. A., McDonald, T. V., Gardner, R. J. Immunol. 152, 5226 (1994)
28. Schilling, W. P., Cabello, O. A., Rajan, L., Biochem J. 284, 521 (1992)
29. Vostal, J. G., Fratantoni, J. C. Biochem J. 295, 525 (1993)
30. Demaurex, N., Monod, A., Lew, D. P., Krause, K. H., Biochem J. 297, 595 (1994)